| Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotypes M Lopez-Siles, M Martinez-Medina, D Busquets, M Sabat-Mir, SH Duncan, ... International journal of medical microbiology 304 (3-4), 464-475, 2014 | 153 | 2014 |
| Total enteral nutrition vs. total parenteral nutrition in patients with severe acute pancreatitis M Casas, J Mora, E Fort, C Aracil, D Busquets, S Galter, CE Jáuregui, ... Revista Espanola de Enfermedades Digestivas 99 (5), 264, 2007 | 135 | 2007 |
| Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-term follow-up study MJ Casanova, M Chaparro, V García-Sánchez, O Nantes, E Leo, ... Official journal of the American College of Gastroenterology| ACG 112 (1 …, 2017 | 114 | 2017 |
| Mucosa-associated Faecalibacterium prausnitzii phylotype richness is reduced in patients with inflammatory bowel disease M Lopez-Siles, M Martinez-Medina, C Abellà, D Busquets, M Sabat-Mir, ... Applied and environmental microbiology 81 (21), 7582-7592, 2015 | 109 | 2015 |
| Clinical outcomes of golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis C Taxonera, C Rodriguez, F Bertoletti, L Menchen, J Arribas, M Sierra, ... Inflammatory bowel diseases 23 (8), 1394-1402, 2017 | 92 | 2017 |
| Anti-tumour necrosis factor treatment with adalimumab induces changes in the microbiota of Crohn’s disease D Busquets, T Mas-de-Xaxars, M López-Siles, M Martínez-Medina, A Bahí, ... Journal of Crohn's and Colitis 9 (10), 899-906, 2015 | 74 | 2015 |
| Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case‐control study M Mañosa, M Calafat, R De Francisco, C García, MJ Casanova, P Huelín, ... Alimentary pharmacology & therapeutics 47 (5), 605-614, 2018 | 73 | 2018 |
| Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry M Chaparro, A Garre, F Mesonero, C Rodríguez, M Barreiro-de Acosta, ... Journal of Crohn's and Colitis 15 (1), 35-42, 2021 | 72 | 2021 |
| Real‐world short‐term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry M Iborra, B Beltrán, A Fernández‐Clotet, A Gutiérrez, B Antolín, ... Alimentary pharmacology & therapeutics 50 (3), 278-288, 2019 | 69 | 2019 |
| Current concepts on microscopic colitis: evidence‐based statements and recommendations of the Spanish Microscopic Colitis Group F Fernández‐Bañares, MJ Casanova, Y Arguedas, B Beltrán, D Busquets, ... Alimentary Pharmacology & Therapeutics 43 (3), 400-426, 2016 | 65 | 2016 |
| Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from the ENEIDA registry M Chaparro, A Garre, M Iborra, M Sierra-Ausín, M Barreiro-de Acosta, ... Journal of Crohn's and Colitis 15 (11), 1846-1851, 2021 | 61 | 2021 |
| Real‐world long‐term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry M Iborra, B Beltrán, A Fernández‐Clotet, E Iglesias‐Flores, P Navarro, ... Alimentary Pharmacology & Therapeutics 52 (6), 1017-1030, 2020 | 54 | 2020 |
| Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation C Taxonera, E Iglesias, F Muñoz, M Calvo, M Barreiro-de Acosta, ... Digestive diseases and sciences 62, 481-490, 2017 | 52 | 2017 |
| Increased risk of thiopurine‐related adverse events in elderly patients with IBD M Calafat, M Mañosa, F Cañete, E Ricart, E Iglesias, M Calvo, ... Alimentary Pharmacology & Therapeutics 50 (7), 780-788, 2019 | 47 | 2019 |
| Long-term real-world effectiveness and safety of ustekinumab in Crohn’s disease patients: the SUSTAIN study M Chaparro, I Baston-Rey, E Fernández-Salgado, J González García, ... Inflammatory Bowel Diseases 28 (11), 1725-1736, 2022 | 41 | 2022 |
| Extraintestinal manifestations in patients with inflammatory bowel disease: study based on the ENEIDA Registry A Algaba, I Guerra, E Ricart, E Iglesias, M Mañosa, JP Gisbert, ... Digestive Diseases and Sciences 66, 2014-2023, 2021 | 38 | 2021 |
| Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry X Andújar, C Loras, B González, M Socarras, V Sanchiz, M Boscà, ... Surgical Endoscopy 34, 1112-1122, 2020 | 35* | 2020 |
| Correlation between anti-TNF serum levels and endoscopic inflammation in inflammatory bowel disease patients M Chaparro, M Barreiro-de Acosta, A Echarri, R Almendros, J Barrio, ... Digestive Diseases and Sciences 64, 846-854, 2019 | 32 | 2019 |
| Influence of a nucleotide oligomerization domain 1 (NOD1) polymorphism and NOD2 mutant alleles on Crohn's disease phenotype E Cantó, E Ricart, D Busquets, D Monfort, E García-Planella, D González, ... World Journal of Gastroenterology: WJG 13 (41), 5446, 2007 | 28 | 2007 |
| Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial C Loras, X Andújar, JB Gornals, V Sanchiz, E Brullet, B Sicilia, ... The Lancet Gastroenterology & Hepatology 7 (4), 332-341, 2022 | 23 | 2022 |
